Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 14, Number 6—June 2008
Letter

Lethal Mycobacterium massiliense Sepsis, Italy

On This Page
Tables
Article Metrics
21
citations of this article
EID Journal Metrics on Scopus

Cite This Article

To the Editor: A strain of Mycobacterium massiliense was isolated from the blood of a kidney transplant patient in Italy at the same time she was diagnosed as having pulmonary tuberculosis. M. massiliense bacteremia appears to have played a role in her sudden death.

The patient, a 63-year-old woman who had had a kidney transplant 10 years earlier and was receiving immunosuppressive treatment with cyclosporine, azathioprine, and prednisolone, was hospitalized in an intensive care unit because of septic shock, a stuporous condition, hypotension, respiratory insufficiency, and acute renal failure. Results of initial microbiologic investigations (cultures of blood, urine, and bronchial aspirate, and nasal and pharyngeal swabs; tests for antigens of Legionella pneumophila, pneumococcus, and Cryptococcus neoformans; and serologic analysis for pneumotropic viruses and bacteria) were negative.

Hematologic analysis showed leukopenia with high neutrophil counts. Septic shock–specific therapy was given along with wide-spectrum antimicrobial drug therapy (levofloxacin, trimethoprim-sulfamethoxazole, piperacillin-tazobactam, and fluconazole). After moderate improvement, the patient’s general condition worsened and prompted a new round of microbiologic tests, including those for mycobacteria. After acid-fast bacilli were detected in a bronchial aspirate and results of nucleic acid amplification (Amplicor; Roche, Basel, Switzerland) were positive for M. tuberculosis complex, she was given standard antituberculosis treatment. She died the next day.

Three blood cultures obtained 7 days before the death of the patient showed positive results in aerobic bottles but not in anaerobic bottles (BacT/ALERT SA; bioMérieux, Marcy l’Etoile, France). Subcultures spread onto blood agar yielded small white colonies of gram-positive bacilli, including branched forms, within 24 hours. One month earlier, the patient had been seen as an outpatient with intermittent fever, and unidentified gram-positive bacilli were observed in her blood culture.

Genetic sequencing of the first one third of the 16S rDNA gene (1) of the strain (GenBank accession no. EU370523) showed 99.8% identity with M. abscessus, M. bolletii, M. chelonae, and M. massiliense. To discriminate between these 4 species, a 723-bp fragment of the RNA polymerase β subunit (rpoB) gene (2) also was sequenced (GenBank accession no. EU370524). Sequencing showed 100% similarity with M. massiliense; the next most closely related species was M. bolletii (98.6% similarity).

An isolate of M. tuberculosis that was susceptible to all first-line antituberculosis drugs was recovered from this patient’s bronchial aspirate in both solid and liquid media. Immunocompromised patients, including those with organ transplants, are known to be prone to mycobacterial infections (3). Mixed mycobacterial infections also have been reported (4). This newly described species has been isolated from pulmonary fluids (5), blood (6), intramuscular injection sites (7), and surgical wounds (8). Because sequencing 16S rDNA does not differentiate M. abscessus, M. bolletii, M. chelonae, and M. massiliense (5), use of the rpoB sequence is crucial.

As reported for isolates of M. massiliense (58), our isolate was characterized by high MICs (9) (broth microdilution by using the Sensititer RGMYCO; Trek Diagnostic Systems Inc., Cleveland, OH, USA) to most of the antimicrobial drugs tested. The isolate was sensitive only to clarithromycin and amikacin and showed borderline sensitivity to linezolid (Table).

Despite co-infection with M. tuberculosis, the patient’s death was likely caused by M. massiliense bacteremia. The patient died before the isolate was identified as a mycobacterium, and unfortunately, none of the drugs used empirically was active against this organism.

Only speculations can be made about how this patient acquired the M. massiliense infection. However, 5 months before her hospital admission, the patient had received a coxofemoral arthroprosthesis as a result of a fall and had since complained of generalized bone pain and had remained bedridden. Although in this case no proof exists, infection caused by rapidly growing mycobacteria after surgical intervention (10) is well known and should be considered.

M. massiliense has been distinguished from M. abscessus by sequencing of the rpoB gene (2). Because this technology is available in relatively few clinical laboratories, cases of infection with M. massiliense may be mistakenly attributed to M. abscessus. Although infections with M. massiliense may be underrecognized, reports of these infections are raising concern. The capacity of this bacteria to infect different body sites is further evidence for the pathogenic potential of a rapidly growing mycobacteria in human infections (10).

Top

Enrico Tortoli*Comments to Author , Rita Gabini†, Irene Galanti†, and Alessandro Mariottini*

Author affiliations: *Careggi Hospital, Florence, Italy; †San Donato Hospital, Arezzo, Italy;

Top

References

  1. Böddinghaus  B, Rogall  T, Flohr  T, Blöcker  H, Böttger  EC. Detection and identification of mycobacteria by amplification of rRNA. J Clin Microbiol. 1990;28:17519.PubMed
  2. Adékambi  T, Colson  P, Drancourt  M. rpoB-based identification of nonpigmented and late-pigmenting rapidly growing mycobacteria. J Clin Microbiol. 2003;41:5699708. DOIPubMed
  3. Delaney  V, Sumrani  N, Hong  JH, Sommer  B. Mycobacterial infections in renal allograft recipients. Transplant Proc. 1993;25:22889.PubMed
  4. Branger  B, Gouby  A, Oulès  R, Barducci  JP, Mourad  G, Fourcade  J, Mycobacterium haemophilum and Mycobacterium xenopi associated infection in a renal transplant patient. Clin Nephrol. 1985;23:469.PubMed
  5. Adékambi  T, Reynaud-Gaubert  M, Greub  G, Gevaudan  MJ, La Scola  B, Raoult  D, Amoebal coculture of “Mycobacterium massiliense” sp. nov. from the sputum of a patient with hemoptoic pneumonia. J Clin Microbiol. 2004;42:5493501. DOIPubMed
  6. Simmon  KE, Pounder  JI, Greene  JN, Walsh  F, Anderson  CM, Cohen  S, Identification of an emerging pathogen, Mycobacterium massiliense, by rpoB sequencing of clinical isolates collected in the United States. J Clin Microbiol. 2007;45:197880. DOIPubMed
  7. Kim  HY, Yun  YJ, Park  CG, Lee  BH, Cho  YK, Park  BJ, Outbreak of Mycobacterium massiliense infection associated with intramuscular injections. J Clin Microbiol. 2007;45:312730. DOIPubMed
  8. Viana-Niero  C, Lima  KV, Lopes  ML, da Silva Rabello  MC, Marsola  LR, Brilhante  VC, Molecular characterization of Mycobacterium massiliense and Mycobacterium bolletii in outbreaks of infections after laparoscopic surgeries and cosmetic procedures. J Clin Microbiol. 2008;46:8505. DOIPubMed
  9. Clinical and Laboratory Standards Institute (CLSI). Susceptibility testing of Mycobacteria, Nocardia, and other aerobic actinomycetes: approved standard M24-A. Wayne (PA): The Institute; 2003.
  10. Brown-Elliott  BA, Wallace  RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. Clin Microbiol Rev. 2002;15:71646. DOIPubMed

Top

Table

Top

Cite This Article

DOI: 10.3201/eid1406.080194

Related Links

Top

Table of Contents – Volume 14, Number 6—June 2008

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Enrico Tortoli, Regional Reference Center for Mycobacteria, Microbiology Laboratory, Careggi Hospital, Viale Morgagni 85, 50134 Florence, Italy;

Send To

character(s) remaining.

Comment submitted successfully, thank you for your feedback.

Top

Page created: July 09, 2010
Page updated: July 09, 2010
Page reviewed: July 09, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external